SC12267
- Generic Name
- SC12267
- Drug Type
- Small Molecule
- Background
SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.
- Indication
Investigated for use/treatment in multiple sclerosis and rheumatoid arthritis.
SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2012-03-01
- Lead Sponsor
- 4SC AG
- Target Recruit Count
- 266
- Registration Number
- NCT01010581
- Locations
- 🇧🇬
UMHAT "Sveti Ivan Rilski", Sofia, Bulgaria
🇵🇱Śląskie Centrum Osteoporozy, Katowice, Poland
🇵🇱Wojewódzki Szpital Reumatologiczny, Sopot, Poland
SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
- Conditions
- Inflammatory Bowel Disease (IBD)
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2011-05-18
- Lead Sponsor
- 4SC AG
- Target Recruit Count
- 34
- Registration Number
- NCT00820365
- Locations
- 🇩🇪
Schwerpunktpraxis für chronisch entzündliche Darmerkrankungen, Hamburg, Germany
🇩🇪Universitätsklinikum Regensburg Klinik und Poliklinik für Innere Medizin I, Regensburg, Germany
🇷🇴University Emergency Hospital, Bucuresti, Romania
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.